Cell-based serum anticholinergic activity assay and working memory in cognitively healthy older adults before and after scopolamine: An exploratory study
Restricted accessResearch articleFirst published online September, 2022
Cell-based serum anticholinergic activity assay and working memory in cognitively healthy older adults before and after scopolamine: An exploratory study
A new cell-based serum anticholinergic activity (cSAA) assay that measures anticholinergic activity specifically at muscarinic M1 receptors and eliminates many of the drawbacks of the existing assay was developed by our team.
Aims:
We aimed to study the relationship between changes in working memory and executive function with changes in cSAA using the new assay in cognitively healthy older adults.
Methods:
Cognitively healthy participants aged 50 years and above, received a single dose of 0.4 mg of intravenous scopolamine. Cognition and cSAA levels were measured before and 30 min after receiving scopolamine. Cognition was measured using the Cambridge Neuropsychological Test Automated Battery.
Results:
Ten participants were recruited, and nine (mean age = 69.8, SD = 9.5, range 59–86 years) completed the study. Following scopolamine, participants experienced an increase in cSAA (cSAA pre = 0.90 ± 0.97 vs cSAA post = 12.0 ± 3.70 pmol/L; t-test (df = (8) = −9.5, p < 0.001). In addition, there was an association between change in cSAA and changes in working memory (Spearman’s ρ = 0.68, p = 0.042) and executive function (Spearman’s ρ = 0.72, p = 0.027).
Conclusions:
In our sample of cognitively healthy older adults, the new cSAA assay was able to quantify the scopolamine induced increase in anticholinergic load which correlated significantly with the observed decline in working memory and executive function.
AbramsPAnderssonKEBuccafuscoJJ, et al. (2006) Muscarinic receptors: Their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol148: 565–578.
2.
AnagnostarasSGMurphyGGHamiltonSE, et al. (2003) Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci6: 51–58.
3.
AncelinMLArteroSPortetF, et al. (2006) Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: Longitudinal cohort study. BMJ332: 455–459.
4.
BroksPPrestonGCTraubM, et al. (1988) Modelling dementia: Effects of scopolamine on memory and attention. Neuropsychologia26: 685–700.
5.
CaiXCampbellNKhanB, et al. (2013) Long-term anticholinergic use and the aging brain. Alzheimers Dement9: 377–385.
6.
CardwellKHughesCMRyanC (2015) The association between anticholinergic medication burden and health related outcomes in the ‘oldest old’: A systematic review of the literature. Drugs Aging32: 835–848.
7.
CarnahanRMLundBCPerryPJ, et al. (2002) A critical appraisal of the utility of the serum anticholinergic activity assay in research and clinical practice. Psychopharmacol Bull36: 24–39.
8.
CarriereIFourrier-ReglatADartiguesJF, et al. (2009) Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: The 3-city study. Arch Intern Med169: 1317–1324.
9.
ChandramouleeshwaranSAhsanNRaymondR, et al. (2021) Relationships between a new cultured cell-based serum anticholinergic activity assay and anticholinergic burden scales or cognitive performance in older adults. Am J Geriatr Psychiatry29: 1239–1252.
10.
ChewMLMulsantBHPollockBG, et al. (2008) Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc56: 1333–1341.
11.
CoxEAKwatraSGShettyS, et al. (2009) Flaws in the serum anticholinergic activity assay: Implications for the study of delirium. J Am Geriatr Soc57: 1707–1708.
12.
DemeterESarterM (2013) Leveraging the cortical cholinergic system to enhance attention. Neuropharmacology64: 294–304.
13.
EbertUSiepmannMOertelR, et al. (1998) Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. J Clin Pharmacol38: 720–726.
14.
FirstMBSpitzerRGibbonM, et al. (2002) Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute.
15.
FredricksonASnyderPJCromerJ, et al. (2008) The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: An example with scopolamine. Hum Psychopharmacol23: 425–436.
16.
GerretsenPPollockBG. (2011) Drugs with anticholinergic properties: A current perspective on use and safety. Expert Opin Drug Saf10: 751–765.
17.
GreenARReiflerLMBaylissEA, et al. (2019) Drugs contributing to anticholinergic burden and risk of fall or fall-related injury among older adults with mild cognitive impairment, dementia and multiple chronic conditions: A retrospective cohort study. Drugs Aging36: 289–297.
18.
GuptaDChenPP (2016) Glaucoma. Am Fam Physician93: 668–674.
19.
HanLAgostiniJVAlloreHG (2008) Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc56: 2203–2210.
20.
HasselmoMESarterM. (2011) Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology36: 52–73.
21.
HilmerSNMagerDESimonsickEM, et al. (2009) Drug burden index score and functional decline in older people. Am J Med122: 1142–1149.
22.
HughesCPBergLDanzigerWL, et al. (1982) A new clinical scale for the staging of dementia. Br J Psychiatry140: 566–572.
23.
JovaisasBFarnhamJ (2014) Compendium of Therapeutic Choices, CTC 7. Ottawa, ON: Canadian Pharmacists Association.
24.
KerstenHWyllerTB. (2014) Anticholinergic drug burden in older people’s brain – how well is it measured?Basic Clin Pharmacol Toxicol114: 151–159.
25.
KlinkenbergIBloklandA. (2010) The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies. Neurosci Biobehav Rev34: 1307–1350.
26.
LampelaPPaajanenTHartikainenS, et al. (2015) Central anticholinergic adverse effects and their measurement. Drugs Aging32: 963–974.
27.
LenzRABakerJDLockeC, et al. (2012) The scopolamine model as a pharmacodynamic marker in early drug development. Psychopharmacology (Berl)220: 97–107.
28.
LeveyAIKittCASimondsWF, et al. (1991) Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci11: 3218–3226.
29.
MolchanSEMartinezRAHillJL, et al. (1992) Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev17: 215–226.
30.
NasreddineZSPhillipsNBédirianV, et al. (2005) The montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc53: 695–699.
31.
NobregaJNRaymondRJPollockBG. (2017) An improved, high-efficiency assay for assessing serum anticholinergic activity using cultured cells stably expressing M1 receptors. J Pharmacol Toxicol Methods86: 28–33.
PrumBEJrHerndonLWJrMoroiSE, et al. (2016) Primary angle closure preferred practice pattern((R)) guidelines. Ophthalmology123: P1–P40.
34.
PutchaLCintronNMTsuiJ, et al. (1989) Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. Pharm Res6: 481–485.
35.
RajjiTKMulsantBHDaviesS, et al. (2015) Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine. Am J Psychiatry172: 579–585.
36.
RennerUDOertelRKirchW (2005) Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Ther Drug Monit27: 655–665.
37.
SalahudeenMSChyouTYNishtalaPS (2016) Serum anticholinergic activity and cognitive and functional adverse outcomes in older people: A systematic review and meta-analysis of the literature. PLoS One11: e0151084.
38.
SalahudeenMSDuffullSBNishtalaPS (2015) Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: A systematic review. BMC Geriatr15: 31.
39.
SalahudeenMSNishtalaPSDuffullSB. (2016) The influence of patient characteristics on anticholinergic events in older people. Dement Geriatr Cogn Dis Extra5: 530–541.
40.
SnyderPJBednarMMCromerJR, et al. (2005) Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor. Alzheimers Dement1: 126–135.
41.
StraussEShermanESpreenO. (2006) A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, 3rd edn.Oxford: Oxford University Press.
42.
TuneLCoyleJT (1980) Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Arch Gen Psychiatry37: 293–297.
43.
TuneLCoyleJT (1981) Acute extrapyramidal side effects: Serum levels of neuroleptics and anticholinergics. Psychopharmacology (Berl)75: 9–15.
44.
UusvaaraJPitkalaKHKautiainenH, et al. (2013) Detailed cognitive function and use of drugs with anticholinergic properties in older people: A community-based cross-sectional study. Drugs Aging30: 177–182.
45.
XiongCHLiuMGZhaoLX, et al. (2019) M1 muscarinic receptors facilitate hippocampus-dependent cognitive flexibility via modulating GluA2 subunit of AMPA receptors. Neuropharmacology146: 242–251.
